Amber Chaney, in Booneville, KY - Registered Nurse

Amber Chaney, is a Registered Nurse based in Booneville, Kentucky. Amber Chaney is licensed to practice in Kentucky (license number 1136009) and her current practice location is 310 Stone Coal Creek Rd, Booneville, Kentucky. She can be reached at her office (for appointments etc.) via phone at (606) 272-2792.

NPI number for Amber Chaney is 1538615968 and her current mailing address is 310 Stone Coal Creek Rd, Booneville, Kentucky. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1538615968.

Contact Information

	Amber Chaney,
	310 Stone Coal Creek Rd, Booneville, KY 41314-9504
	(606) 272-2792
	Not Available

Provider's Profile

Full Name	Amber Chaney
Gender	Female
Speciality	Registered Nurse
Location	310 Stone Coal Creek Rd, Booneville, Kentucky
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1538615968
Provider Enumeration Date: 08/26/2016
Last Update Date: 08/26/2016

Medical Identifiers

Medical identifiers for Amber Chaney such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1538615968	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
163W00000X	Registered Nurse	1136009 (Kentucky)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Amber Chaney is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Amber Chaney, 310 Stone Coal Creek Rd, Booneville, KY 41314-9504 Ph: () -	Amber Chaney, 310 Stone Coal Creek Rd, Booneville, KY 41314-9504 Ph: (606) 272-2792

News Archive

Experimental vaccine protects cynomolgus macaques against Crimean-Congo hemorrhagic fever virus

An experimental vaccine developed in Europe to prevent infection by Crimean-Congo hemorrhagic fever virus (CCHFV) has protected cynomolgus macaques in a new collaborative study from National Institutes of Health scientists.

Uganda plans survey to determine prevalence of MDR-TB, health official says

Uganda this year plans to conduct a survey to determine the prevalence of multi-drug resistant tuberculosis in the country, National Leprosy and TB program manager Francis Adatu said Wednesday, the Monitor reports.

Patients with SVT more likely to develop venous thromboembolism

Patients with clinically diagnosed superficial vein thrombosis (SVT), a blood clot in the veins just beneath the skin that commonly resolves on its own without treatment, are four to six times more likely to develop venous thromboembolism (VTE), a dangerous, often life-threatening condition, according to study results published today in Blood, the Journal of the American Society of Hematology.

Ranbaxy receives FDA approval to manufacture and market generic Lipitor

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.

Amber Chaney, - Registered Nurse in Booneville, KY